We Must Improve Vaccine Manufacturing Before the Next Virus

It should worry everyone that experts surveyed by TIME regarded both increasing funding in a post-COVID-19 world for vaccine development and scaling up of manufacturing capacity feasible—but improving equitable vaccine distribution was not.

To stop the next pandemic in its tracks, we need to ensure that people worldwide are protected quickly, and that will entail having all these pieces in place. The good news is, all these elements are feasible and indeed starting to work today.

On vaccine R&D, the Coalition for Epidemic Preparedness Innovations (CEPI) was set up with the precise purpose of identifying and investing in R&D for vaccines against emerging infectious diseases with epidemic potential. So, when it came to COVID-19, with CEPI’s and other R&D support, as well as industry engagement, the scientific and vaccine manufacturing community rallied, producing the first safe and effective vaccine in record time—just 327 days. Today we have not just one but 15 in widespread use.

Increased investment now could get us there even faster the next time, particularly given the potential of the relatively new RNA vaccine technologies that have proved so effective with COVID-19. These plug-and-play vaccine technologies not only make it possible to identify and develop antigens rapidly but much of the regulatory testing and approval can be done in advance, even before we know what the threat is.

 

As for manufacturing, it may be difficult to immediately discern when there are severe supply shortages, but the world has actually rapidly built up manufacturing capacity during COVID-19. Waiving intellectual property has been talked about a lot as a potential solution for boosting production. But the growth we have seen in the past year has been achieved through technology transfers, where both the intellectual property and the vital know-how needed to make vaccines is shared between manufacturers.

However, we need to do more. Given the massive number of doses required during a pandemic, export bans of vaccines and essential components and supply bottlenecks have led to a vaccine divide. Currently, more than a third of adults in high-income countries have now been vaccinated, while less than 1% of those in low-income countries have had their first jab.

To prevent this kind of scenario from happening the next time around and ensure that those most at risk are prioritized, it is not distribution channels we lack but global manufacturing capacity. We already have highly effective distribution channels through COVAX and its partners. We already have access to doses enough to protect 1.8 billion people in lower-income economies by early next year, enough to protect almost 30% of people in these countries. But through investments now to increase global manufacturing capacity, particularly in emerging economies, and support of technology transfers, the next time a pandemic strikes, we can get there sooner.

The Coronavirus Brief. Everything you need to know about the global spread of COVID-19

Thank you!

For your security, we’ve sent a confirmation email to the address you entered. Click the link to confirm your subscription and begin receiving our newsletters. If you don’t get the confirmation within 10 minutes, please check your spam folder.

Contact us at letters@time.com.

Tyson Houlding
Tyson Houlding is a 28-year-old associate at a law firm who enjoys walking, writing, and learning new languages. He is creative and bright, but can also be very unfriendly and a bit lazy.He is an Australian Christian who defines himself as straight. He has a post-graduate degree in law.